Krystal Biotech, Inc. Research and Development Expense
Krystal Biotech, Inc. (KRYS) reported Research and Development Expense of $14.52 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-03
- Krystal Biotech, Inc. research and development expense for the quarter ending 2026-06-30 was $14.52M, a 0.75% increase year-over-year.
- Krystal Biotech, Inc. research and development expense for the quarter ending 2026-03-31 was $15.33M, a 7.54% increase year-over-year.
- Krystal Biotech, Inc. research and development expense for the quarter ending 2025-12-31 was $14.79M, a 9.36% increase year-over-year.
- Krystal Biotech, Inc. research and development expense for the quarter ending 2025-09-30 was $14.59M, a 7.94% increase year-over-year.
- Krystal Biotech, Inc. research and development expense for fiscal 2025 was $58.05M, a 8.33% increase from fiscal 2024.
- Krystal Biotech, Inc. research and development expense for fiscal 2024 was $53.58M, a 15.39% increase from fiscal 2023.
- Krystal Biotech, Inc. research and development expense for fiscal 2023 was $46.43M, a 9.35% increase from fiscal 2022.
- Krystal Biotech, Inc. research and development expense for fiscal 2022 was $42.46M, a 52.28% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $14.52M 10-Q · filed 2026-08-03 | $29.85M 10-Q · filed 2026-08-03 | $44.64M derived: sum of 3 quarters · filed 2026-08-03 | $59.23M derived: sum of 4 quarters · filed 2026-08-03 | |||
| 2026-03-31 | $15.33M 10-Q · filed 2026-05-04 | $30.13M derived: sum of 2 quarters · filed 2026-05-04 | $44.71M derived: sum of 3 quarters · filed 2026-05-04 | $59.12M derived: sum of 4 quarters · filed 2026-08-03 | |||
| 2025-12-31 | $14.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $29.38M derived: sum of 2 quarters · filed 2026-02-17 | $43.79M derived: sum of 3 quarters · filed 2026-08-03 | $58.05M 10-K · filed 2026-02-17 | |||
| 2025-09-30 | $14.59M 10-Q · filed 2025-11-03 | $29.00M derived: sum of 2 quarters · filed 2026-08-03 | $43.25M 10-Q · filed 2025-11-03 | $56.78M derived: sum of 4 quarters · filed 2026-08-03 | |||
| 2025-06-30 | $14.41M 10-Q · filed 2026-08-03 | $28.67M 10-Q · filed 2026-08-03 | $42.19M derived: sum of 3 quarters · filed 2026-08-03 | $55.71M derived: sum of 4 quarters · filed 2026-08-03 | |||
| 2025-03-31 | $14.26M 10-Q · filed 2026-05-04 | $14.26M 10-Q · filed 2025-05-06 | $27.78M derived: sum of 2 quarters · filed 2026-05-04 | $41.30M derived: sum of 3 quarters · filed 2026-05-04 | $56.88M derived: sum of 4 quarters · filed 2026-05-04 | ||
| 2024-12-31 | $13.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $27.04M derived: sum of 2 quarters · filed 2026-02-17 | $42.62M derived: sum of 3 quarters · filed 2026-02-17 | $53.58M 10-K · filed 2026-02-17 | $53.57M 10-K · filed 2025-02-19 | ||
| 2024-09-30 | $13.51M 10-Q · filed 2025-11-03 | $13.51M 10-Q · filed 2024-11-04 | $29.09M derived: sum of 2 quarters · filed 2025-11-03 | $40.05M 10-Q · filed 2025-11-03 | $40.05M 10-Q · filed 2024-11-04 | $51.42M derived: sum of 4 quarters · filed 2026-02-17 | |
| 2024-06-30 | $15.58M 10-Q · filed 2025-08-04 | $26.54M 10-Q · filed 2025-08-04 | $37.91M derived: sum of 3 quarters · filed 2026-02-17 | $48.54M derived: sum of 4 quarters · filed 2026-02-17 | |||
| 2024-03-31 | $10.96M 10-Q · filed 2025-05-06 | $22.33M derived: sum of 2 quarters · filed 2026-02-17 | $32.96M derived: sum of 3 quarters · filed 2026-02-17 | $45.10M derived: sum of 4 quarters · filed 2026-02-17 | |||
| 2023-12-31 | $11.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $22.00M derived: sum of 2 quarters · filed 2026-02-17 | $34.15M derived: sum of 3 quarters · filed 2026-02-17 | $46.43M 10-K · filed 2026-02-17 | $46.43M 10-K · filed 2024-02-26 | ||
| 2023-09-30 | $10.63M 10-Q · filed 2024-11-04 | $22.77M derived: sum of 2 quarters · filed 2024-11-04 | $35.06M 10-Q · filed 2024-11-04 | $45.80M derived: sum of 4 quarters · filed 2025-02-19 | |||
| 2023-06-30 | $12.14M 10-Q · filed 2024-08-05 | $24.43M 10-Q · filed 2024-08-05 | $35.17M derived: sum of 3 quarters · filed 2025-02-19 | $46.69M derived: sum of 4 quarters · filed 2025-02-19 | |||
| 2023-03-31 | $12.29M 10-Q · filed 2024-05-06 | $23.03M derived: sum of 2 quarters · filed 2025-02-19 | $34.55M derived: sum of 3 quarters · filed 2025-02-19 | $45.44M derived: sum of 4 quarters · filed 2025-02-19 | |||
| 2022-12-31 | $10.74M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $22.26M derived: sum of 2 quarters · filed 2025-02-19 | $33.15M derived: sum of 3 quarters · filed 2025-02-19 | $42.46M 10-K · filed 2025-02-19 | |||
| 2022-09-30 | $11.52M 10-Q · filed 2023-11-06 | $22.41M derived: sum of 2 quarters · filed 2023-11-06 | $31.72M 10-Q · filed 2023-11-06 | $40.73M derived: sum of 4 quarters · filed 2024-02-26 | |||
| 2022-06-30 | $10.89M 10-Q · filed 2023-08-07 | $20.20M 10-Q · filed 2023-08-07 | $29.21M derived: sum of 3 quarters · filed 2024-02-26 | $35.29M derived: sum of 4 quarters · filed 2024-02-26 | |||
| 2022-03-31 | $9.31M 10-Q · filed 2023-05-08 | $18.32M derived: sum of 2 quarters · filed 2024-02-26 | $24.40M derived: sum of 3 quarters · filed 2024-02-26 | $31.00M derived: sum of 4 quarters · filed 2024-02-26 | |||
| 2021-12-31 | $9.01M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $15.09M derived: sum of 2 quarters · filed 2024-02-26 | $21.68M derived: sum of 3 quarters · filed 2024-02-26 | $27.88M 10-K · filed 2024-02-26 | |||
| 2021-09-30 | $6.08M 10-Q · filed 2022-11-07 | $12.67M derived: sum of 2 quarters · filed 2022-11-07 | $18.88M 10-Q · filed 2022-11-07 | $24.55M derived: sum of 4 quarters · filed 2023-02-27 | |||
| 2021-06-30 | $6.59M 10-Q · filed 2022-08-08 | $12.79M 10-Q · filed 2022-08-08 | $18.47M derived: sum of 3 quarters · filed 2023-02-27 | $23.57M derived: sum of 4 quarters · filed 2023-02-27 | |||
| 2021-03-31 | $6.20M 10-Q · filed 2022-05-09 | $11.87M derived: sum of 2 quarters · filed 2023-02-27 | $16.97M derived: sum of 3 quarters · filed 2023-02-27 | $20.61M derived: sum of 4 quarters · filed 2023-02-27 | |||
| 2020-12-31 | $5.67M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $10.77M derived: sum of 2 quarters · filed 2023-02-27 | $14.41M derived: sum of 3 quarters · filed 2023-02-27 | $17.94M 10-K · filed 2023-02-27 | |||
| 2020-09-30 | $5.10M 10-Q · filed 2021-11-08 | $8.74M derived: sum of 2 quarters · filed 2021-11-08 | $12.26M 10-Q · filed 2021-11-08 | $16.61M derived: sum of 4 quarters · filed 2021-11-08 | |||
| 2020-06-30 | $3.64M 10-Q · filed 2021-08-09 | $7.16M 10-Q · filed 2021-08-09 | $11.51M derived: sum of 3 quarters · filed 2021-08-09 | $15.40M derived: sum of 4 quarters · filed 2021-08-09 | |||
| 2020-03-31 | $3.52M 10-Q · filed 2021-05-10 | $7.87M derived: sum of 2 quarters · filed 2021-05-10 | $11.76M derived: sum of 3 quarters · filed 2021-05-10 | $15.97M derived: sum of 4 quarters · filed 2021-05-10 | |||
| 2019-12-31 | $4.35M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $8.23M derived: sum of 2 quarters · filed 2021-03-01 | $12.45M derived: sum of 3 quarters · filed 2021-03-01 | $15.62M 10-K · filed 2021-03-01 | |||
| 2019-09-30 | $3.88M 10-Q · filed 2020-11-09 | $8.10M derived: sum of 2 quarters · filed 2020-11-09 | $11.27M 10-Q · filed 2020-11-09 | $14.07M derived: sum of 4 quarters · filed 2020-11-09 | |||
| 2019-06-30 | $4.22M 10-Q · filed 2020-08-07 | $7.38M 10-Q · filed 2020-08-07 | $10.19M derived: sum of 3 quarters · filed 2020-08-07 | $12.10M derived: sum of 4 quarters · filed 2020-08-07 | |||
| 2019-03-31 | $3.17M 10-Q · filed 2020-05-04 | $5.97M derived: sum of 2 quarters · filed 2020-05-04 | $7.88M derived: sum of 3 quarters · filed 2020-05-04 | $9.41M derived: sum of 4 quarters · filed 2020-05-04 | |||
| 2018-12-31 | $2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | $4.72M derived: sum of 2 quarters · filed 2020-03-10 | $6.24M derived: sum of 3 quarters · filed 2020-03-10 | $7.76M 10-K · filed 2020-03-10 | |||
| 2018-09-30 | $1.91M 10-Q · filed 2019-11-04 | $3.44M derived: sum of 2 quarters · filed 2019-11-04 | $4.96M 10-Q · filed 2019-11-04 | $6.05M derived: sum of 4 quarters · filed 2019-11-04 | |||
| 2018-06-30 | $1.52M 10-Q · filed 2019-08-05 | $3.04M 10-Q · filed 2019-08-05 | $4.13M derived: sum of 3 quarters · filed 2019-08-05 | $5.49M derived: sum of 4 quarters · filed 2019-08-05 | |||
| 2018-03-31 | $1.52M 10-Q · filed 2019-05-07 | $2.61M derived: sum of 2 quarters · filed 2019-05-07 | $3.96M derived: sum of 3 quarters · filed 2019-05-07 | $4.41M derived: sum of 4 quarters · filed 2019-05-07 | |||
| 2017-12-31 | $1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $2.44M derived: sum of 2 quarters · filed 2018-11-05 | $2.89M derived: sum of 3 quarters · filed 2018-11-05 | $3.21M 10-K · filed 2018-03-12 | |||
| 2017-09-30 | $1.35M 10-Q · filed 2018-11-05 | $1.80M derived: sum of 2 quarters · filed 2018-11-05 | $2.12M 10-Q · filed 2018-11-05 | $2.52M derived: sum of 4 quarters · filed 2018-11-05 | |||
| 2017-06-30 | $446.00K 10-Q · filed 2018-08-06 | $765.00K 10-Q · filed 2018-08-06 | $1.17M derived: sum of 3 quarters · filed 2018-08-06 | $1.41M derived: sum of 4 quarters · filed 2018-08-06 | |||
| 2017-03-31 | $319.00K 10-Q · filed 2018-05-07 | $721.00K derived: sum of 2 quarters · filed 2018-05-07 | $962.00K derived: sum of 3 quarters · filed 2018-05-07 | ||||
| 2016-12-31 | $402.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $643.00K derived: sum of 2 quarters · filed 2018-03-12 | $741.00K 10-K · filed 2018-03-12 | ||||
| 2016-09-30 | $241.00K 10-Q · filed 2017-11-13 | $339.00K 10-Q · filed 2017-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |